

# ALLIANCE FOR LUPUS RESEARCH AND PFIZER'S CTI REQUESTS PROPOSALS FOR BIOTHERAPEUTIC AND SMALL-MOLECULE TARGETS

Pre-Proposal Deadline: October 7, 2016



CTI, or Pfizer's Centers for Therapeutic Innovation, collaborates with leading academic medical centers and foundations nationwide in an effort to speed the translation of novel targets to the clinic. In collaboration with the **ALR**, the world's largest private funder of lupus research, CTI seeks to support the development and translation of promising lupus research.

## Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer's technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

## Pre-proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

All researchers and clinicians whose work meets these criteria are invited to apply.

**Please submit pre-proposals to your Tech Transfer Office by October 7, 2016.**

Please contact Mary Faris at  
[mary.faris@pfizer.com](mailto:mary.faris@pfizer.com) with questions.

## Interest for Fall 2016 – Lupus and Immunometabolism

- Agents affecting intracellular metabolic pathways in immune cells
- Targets related to any of the six major metabolic pathways involved in immunometabolism (glycolysis, the tricarboxylic acid (TCA) cycle, the pentose phosphate pathway, fatty acid oxidation, fatty acid synthesis and amino acid metabolism)
- Biomarker studies and projects without a target are not appropriate for this request for proposals

## What We Look For

- **Validated Therapeutic Drug Target:** Strong link from targeted pathway to disease, and a tractable target
- **Strong project rationale,** demonstrated association between target biology and disease mechanism
- **Novel drug targets** with potential to lead to differentiated drugs
- **Link between target pathway and human disease**
- **Ability to address unmet medical needs**
- **Feasibility:** tractable target, discovery/ development plan

## Modalities

- **Large Molecules** (antibodies, proteins, peptides, ADCs, Fusions)
- **Small Molecules** (target classes include kinases, GPCRs, ion channels, transporters, serine hydrolases, and epigenetic targets)



**Alliance for Lupus Research**

PREVENT. TREAT. CURE.

COLLABORATIVE

ENTREPRENEURIAL

RESULTS-DRIVEN



Centers for Therapeutic Innovation  
[www.PfizerCTI.com](http://www.PfizerCTI.com)